Subscribe to RSS
DOI: 10.1055/a-1589-6301
Baseline Working Memory Predicted Response to Low-Dose Ketamine Infusion in Patients with Treatment-Resistant Depression
Funding Source The study was supported by a grant from Taipei Veterans General Hospital (V106B-020, V107B-010, V107C-181, V108B-012, V110C-025, V110B-002), Yen Tjing Ling Medical Foundation (CI- 110–30), Ministry of Science and Technology, Taiwan (101-2314- B-010-060, 102-2314-B-010-060, 107-2314-B-075-063-MY3, 108-2314-B-075 -037, 110-2314-B-075-026, 110-2314-B-075- 024-MY3) and the Kun-Po Soo Medical Foundation. None of these funding organizations had any role in the study design, data collection, analysis, interpretation of results, writing of the report, and the ultimate decision to submit the paper for publication.
Abstract
Introduction Pretreatment neurocognitive function may predict the treatment response to low-dose ketamine infusion in patients with treatment-resistant depression (TRD). However, the association between working memory function at baseline and the antidepressant efficacy of ketamine infusion remains unclear.
Methods A total of 71 patients with TRD were randomized to one of three treatment groups: 0.5 mg/kg ketamine, 0.2 mg/kg ketamine, or normal saline. Depressive symptoms were measured using the 17-item Hamilton Depression Rating Scale (HDRS) at baseline and after treatment. Cognitive function was evaluated using working memory and go-no-go tasks at baseline.
Results A generalized linear model with adjustments for demographic characteristics, treatment groups, and total HDRS scores at baseline revealed only a significant effect of working memory function (correct responses and omissions) on the changes in depressive symptoms measured by HDRS at baseline (F=12.862, p<0.05). Correlation analysis further showed a negative relationship (r=0.519, p=0.027) between pretreatment working memory function and changes in HDRS scores in the 0.5 mg/kg ketamine group.
Discussion An inverse relationship between pretreatment working memory function and treatment response to ketamine infusion may confirm that low-dose ketamine infusion is beneficial and should be reserved for patients with TRD.
Publication History
Received: 16 June 2021
Received: 03 August 2021
Accepted: 04 August 2021
Article published online:
16 September 2021
© 2021. Thieme. All rights reserved.
Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany
-
References
- 1 Howland RH. Sequenced treatment alternatives to relieve depression (STAR*D). Part 2: Study outcomes. J Psychosoc Nurs Ment Health Serv 2008; 46: 21-24
- 2 Souery D, Papakostas GI, Trivedi MH. Treatment-resistant depression. J Clin Psychiatry 2006; 67: 16-22
- 3 Demyttenaere K, Van Duppen Z. The impact of (the concept of) treatment-resistant depression: an opinion review. Int J Neuropsychopharmacol 2019; 22: 85-92
- 4 Murrough JW, Iosifescu DV, Chang LC. et al. Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial. Am J Psychiatry 2013; 170: 1134-1142
- 5 Su TP, Chen MH, Li CT. et al. Dose-related effects of adjunctive ketamine in Taiwanese patients with treatment-resistant depression. Neuropsychopharmacology 2017; 42: 2482-2492
- 6 Zarate CA, Singh JB, Carlson PJ. et al. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry 2006; 63: 856-864
- 7 Chen MH, Kao CF, Tsai SJ. et al. Treatment response to low-dose ketamine infusion for treatment-resistant depression: A gene-based genome-wide association study. Genomics 2021; 113: 507-514
- 8 Chen MH, Lin WC, Wu HJ. et al. Happiness during low-dose ketamine infusion predicts treatment response: reexploring the adjunctive ketamine study of Taiwanese patients with treatment-resistant depression. J Clin Psychiatry 2020; 81: 20m13232
- 9 Chen MH, Lin WC, Wu HJ. et al. Efficacy of low-dose ketamine infusion in anxious vs nonanxious depression: Revisiting the adjunctive ketamine study of Taiwanese patients with treatment-resistant depression. CNS Spectr 2020; 1-6
- 10 Chen MH, Lin WC, Wu HJ. et al. Interest-activity symptom severity predicts response to ketamine infusion in treatment-resistant depression. Psychopharmacology 2021; 238: 857-865
- 11 Chen MH, Lin WC, Wu HJ. et al. Antisuicidal effect, BDNF Val66Met polymorphism, and low-dose ketamine infusion: Reanalysis of adjunctive ketamine study of Taiwanese patients with treatment-resistant depression (AKSTP-TRD). J Affect Disord 2019; 251: 162-169
- 12 Chen MH, Wu HJ, Li CT. et al. Using classification and regression tree modelling to investigate treatment response to a single low-dose ketamine infusion: post hoc pooled analyses of randomized placebo-controlled and open-label trials. J Affect Disord 2021; 281: 865-871
- 13 Murrough JW, Wan LB, Iacoviello B. et al. Neurocognitive effects of ketamine in treatment-resistant major depression: Association with antidepressant response. Psychopharmacology (Berl). 2013
- 14 Murrough JW, Burdick KE, Levitch CF. et al. Neurocognitive effects of ketamine and association with antidepressant response in individuals with treatment-resistant depression: A randomized controlled trial. Neuropsychopharmacology 2015; 40: 1084-1090
- 15 Zhou Y, Zheng W, Liu W. et al. Neurocognitive effects of six ketamine infusions and the association with antidepressant response in patients with unipolar and bipolar depression. J Psychopharmacol 2018; 32: 1118-1126
- 16 Shiroma PR, Albott CS, Johns B. et al. Neurocognitive performance and serial intravenous subanesthetic ketamine in treatment-resistant depression. Int J Neuropsychopharmacol 2014; 17: 1805-1813
- 17 Zheng W, Zhou YL, Liu WJ. et al. Neurocognitive performance and repeated-dose intravenous ketamine in major depressive disorder. J Affect Disord 2019; 246: 241-247
- 18 Zimmermann PaFB. Test for Attentional Performance (TAP). Psytest Press; Freiburg: 1997
- 19 Chen X, Wang M, Hu Y. et al. Working memory associated with anti-suicidal ideation effect of repeated-dose intravenous ketamine in depressed patients. Eur Arch Psychiatry Clin Neurosci 2021; 271: 431-438
- 20 Salvadore G, Cornwell BR, Sambataro F. et al. Anterior cingulate desynchronization and functional connectivity with the amygdala during a working memory task predict rapid antidepressant response to ketamine. Neuropsychopharmacology 2010; 35: 1415-1422
- 21 Furey ML, Drevets WC, Hoffman EM. et al. Potential of pretreatment neural activity in the visual cortex during emotional processing to predict treatment response to scopolamine in major depressive disorder. JAMA Psychiatry 2013; 70: 280-290
- 22 Stippl A, Scheidegger M, Aust S. et al. Ketamine specifically reduces cognitive symptoms in depressed patients: an investigation of associated neural activation patterns. J Psychiatr Res 2021; 136: 402-408
- 23 Chen MH, Li CT, Lin WC. et al. Cognitive function of patients with treatment-resistant depression after a single low dose of ketamine infusion. J Affect Disord 2018; 241: 1-7
- 24 Wei Y, Chang L, Hashimoto K. Molecular mechanisms underlying the antidepressant actions of arketamine: beyond the NMDA receptor. Mol Psychiatry 2021 DOI: 10.1038/s41380-021-01121-1.